Effect of Anti Phospholipid Antibodies on in vitro fertilization/intracytoplasmic sperm injection outcome

Elham Azimi Nekoo 1 M.D., Ensieh Shahrokh Tehrani Nejad 2,3 M.D., Batool Rashidi 2 M.D., Hossein Kilani 1 Ph.D., Habib Moazami Goudarzi 4 M.D.

1 School of Medicine, Medical Sciences/University of Tehran, Tehran, Iran.
2 Reproductive Health Research Center, Medical Sciences/University of Tehran.
3 Department of Endocrinology, Royan Institute.

Received March 2007; Revised and accepted July 2007.

Abstract

Objective: The study aimed to determine the relationship between presence of antiphospholipid antibodies (APLs) and clinical pregnancy rate in patients undergoing IVF/ICSI procedures.

Materials and methods: This descriptive-analytic study performed on two hundred consecutive women referred for IVF/ICSI in Vali-e-Asr Reproductive Health Research Center. Serum levels of APLs, anticardiolipin [aCL], antiphosphatidic acid [aPA], antiphosphatidyl choline [aPC] and antiphosphatidylserine [aPS] were checked for all patients before starting IVF cycles. APLs seropositivity and clinical pregnancy rate were determined. T-test and Mann-Whitney were used to compare two groups. P value <0.05 was considered significant.

Results: 23 women (11.5%) were APL positive. Twenty nine women of 177 APL seronegative patients (16.4%) became pregnant while only one of 23 seropositive patients (4.3%) was pregnant. Clinical pregnancy rate was not significantly different in two groups.

Conclusion: Although APLs were common, these antibodies did not affect the outcome of IVF/ICSI procedures. Thus screening for APLs is not recommended in women undergoing these procedures.

Key words: Anti phospholipid antibodies, pregnancy rate, In Vitro Fertilization, Intra Cytoplasmic Sperm Injection

Introduction

Antiphospholipid antibodies are a group of antibodies that react with negatively charged phospholipids. These antibodies include anticardiolipin antibody; lupus anticoagulant; antibodies to phosphatidylserine; phosphatidylinositol and phosphatidylethanolamine and antibodies to the cofactor β2 glycoprotein I (a β2 glycoprotein) (1). Antiphospholipid syndrome (APS) has been defined as a condition which history of recurrent pregnancy loss and or thrombosis is accompanied by persistently positive tests for APA (2). Several classes of APLs have been described. The presence of these antibodies, coupled with the clinical manifestations of recurrent miscarriage, arterial or venous thrombosis, or thrombocytopenia in the presence of
overt autoimmune disease, has been termed “Primary Antiphospholipid Syndrome” (3). The importance of this syndrome as an etiologic factor in some cases of recurrent miscarriage is now well established, as is the efficacy of thromboprophylactic treatment with low-dose aspirin and heparin in this group of women (4, 5).

In recent years, one of the greatest controversies in assisted reproduction has been whether the presence of antiphospholipid antibodies (APLs) in the serum of the female partner negatively influences the outcome of IVF/ICSI. Many studies have examined this purported association with variable conclusions (6-24). This question has clinical relevance. The success of aspirin and heparin in the treatment of APL-recurrent miscarriage (4,5) together with the few reports suggesting a possible role for APLs in the failure of IVF/ICSI has led to speculation about whether treatment with aspirin and heparin can improve pregnancy rates in women undergoing IVF/ICSI who have circulating APLs . For example two investigators have proposed aspirin, IVIG and heparin as treatment that might increase the likelihood of implantation in patients seropositive for APL (6, 21). In an other study the use of heparin and aspirin have not increased the success of IVF in patients with APLs (1).

The aims of this study were to determine the prevalence of APLs in women referred for IVF/ICSI and to compare the early outcomes of pregnancy in APL seropositive patients in comparison to APL seronegative patients.

Material and methods

Two hundred women referred to Vali-e-Asr Reproductive Health Research Center for IVF/ICSI between April 2002 and March 2003 were recruited to the study. Exclusion criteria were history of autoimmune diseases, history of recurrent miscarriages or clinical thrombosis and patients’ dissatisfaction. All patients underwent controlled ovarian hyperstimulation (COH) with GnRH agonists and hMG. Before starting IVF/ICSI cycles, blood samples were taken to determine the presence of aCL, aPC, aPS and aPA antibodies. All blood samples were immediately tested for the presence of both IgG and IgM serotypes of aforementioned autoantibodies by standardized enzyme immunoassay (EIA). Values more than 10 U/ml were considered positive.

Early outcomes of pregnancy including the rates of clinical pregnancy (documented by detection of fetal heart activity by ultrasonography two weeks after positive pregnancy test), chemical pregnancy (detection of β-hCG in woman’s serum), blighted ovum (detection of large gestational sac without fetal pole) and multiple pregnancy were compared between two groups. Serum β-hCG measurements were performed two to three weeks after oocyte retrieval.

After collecting the data, SPSS 11 software was used for statistical analysis of this cross sectional descriptive analytic study. T-test and Mann-Whitney were used to compare two groups. Fisher’s exact test was used for other comparisons between APL-positive and APL-negative patients. P-value <0.05 was considered significant.

Results

Two hundred patients were studied in this study with the mean age of 28.9 years; ranging 18-48. Totally 23 patients (11.5%) were seropositive for at least one of APL antibodies. All the 23 patients were aCL antibody positive (IgG or IgM). The mean age of patients was not significantly different in
seropositive and seronegative groups (28 years and 29 years respectively).
Duration of infertility ranged from 1- 21 years with a mean of 6.7 years in studied women. Duration of infertility was not significantly different between two studied groups (6.4 versus 6.8 years).
The prevalence of APL seropositivity was not significantly different between the groups of patients with primary and secondary infertility (10.6% and 15.4% respectively).
With respect to the number of previous IVF/ICSI cycles, patients were divided into 2 groups: patients with 3 or less (181 patients or 90.5%) and patients with more than 3 times of previous cycles, i.e. recurrent IVF/ICSI failure (19 patients or 9.5%). The prevalence of APL antibodies in these two groups was 11% and 15.8%, respectively with no significant difference.
Of 200 women, gestational sac was detected in 32 patients (16%). In 30 patients (15%) fetal heart activity was detected by ultrasonography. Only two cases (1%) of blighted ovum pregnancies, occurred in seronegative patients. The rates of clinical pregnancy and multiple pregnancy were not different in seropositive and seronegative groups (table 1).
Also there was no significant difference in clinical pregnancy rates between seropositive and seronegative groups with respect to age, number of previous IVF/ICSI cycles, type of infertility, duration of infertility and cause of infertility.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>APLs positive (n=23)</th>
<th>APLs negative (n=177)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical pregnancy</td>
<td>3 (13%)</td>
<td>31 (17.5%)</td>
<td>NS</td>
</tr>
<tr>
<td>Clinical pregnancy</td>
<td>1 (4.3%)</td>
<td>29 (16.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Blighted ovum</td>
<td>0</td>
<td>2 (1.1%)</td>
<td>NS</td>
</tr>
<tr>
<td>Multiple pregnancy</td>
<td>0</td>
<td>4 (2.3%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

### Discussion

The role of APL antibodies in infertility and recurrent pregnancy loss has been the focus of several clinical reports (1-5). In recent years, this association has led some investigators to speculate that APL antibodies may also be associated with IVF failure (6-11). The results of such studies are very much conflicting and this question has been one of the greatest controversies in assisted reproduction.
In our study, the prevalence of APLs in infertile women undergoing IVF or ICSI procedures was 11.5%. This was higher than the prevalence of APL antibodies in low-risk population (25, 26). This high prevalence can not be attributed to COH regimen because samples were taken before initiation of cycles. In previous similar studies, the prevalence of APL antibodies varies from 15% to 53% (15, 21) which is attributed to the lack of standardization in APL laboratory testing. In our patient population, the prevalence of APLs was lower than other similar studies which can be due to the different demographic characteristics of patients under study, lack of standardization in antibody testing and missing the measurement of some
measurable antibodies because of our limitations.
This study has demonstrated that despite of the high prevalence of APL antibodies in women referred for IVF/ICSI, these antibodies do not affect the outcome of IVF/ICSI procedures. It is suggested that routine screening of women undergoing IVF/ICSI for the presence of APL antibodies is not recommended.
The role of APLs as a cause of infertility is uncertain, though, a group of candidates for infertility treatment are APL seropositive simultaneously. Regardless of the cause and effect relation, APLs are discussed in different aspects of infertility as below.
Udoff LC, et al considered that the medications used for ovulation induction cause an increase in ovarian estrogen production beyond that typical of a normal menstrual cycle and suggested clinicians to be appropriately concerned about the potential adverse effects of this estrogen surge on the clinical status of women with autoimmune disease (27). For APS, a primary concern would be that of thrombosis or embolism (27). Houg DL and et al showed that the presence of antiphospholipid antibodies increases the thrombotic risk related to ovulation induction therapy especially in systemic Lupus erythematosus patients (28). In other studies APL were shown to be significantly associated with late pregnancy losses (29, 30).
A group of studies present women with endometriosis marking antiphospholipid antibodies more often than women without endometriosis (31)
In conclusion apart of our finding in present study which denies APL screening in all IVF patients, considering other systemic effects of APLs it is justified to perform APLs evaluation in the group of indicated patients.
Although APLs were common, these antibodies did not affect the outcome of IVF/ICSI procedures. Thus screening for APLs is not routinely recommended in all women undergoing IVF/ICSI and its performance should be considered in only indicated cases.

References

3- Harris EN. Clinical and serological features of the antiphospholipid syndrome (APS). Br J Rheumatol 1987; 26: 19.
10- Coulam CB, Kaider BD, Kaider AS, Janowicz P, Roussev RG. Antiphospholipid antibodies associated...


